<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel disease</z:e> (IBD) is comprised of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, both <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory <z:e sem="disease" ids="C0021831" disease_type="Disease or Syndrome" abbrv="">intestinal disorders</z:e> of unknown etiology characterized by a waxing and waning clinical course </plain></SENT>
<SENT sid="1" pm="."><plain>For many years, the drug therapy was limited to <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> and related aminosalicylates, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and antibiotics </plain></SENT>
<SENT sid="2" pm="."><plain>Studies suggesting that the pathophysiology of these disorders relates to a disregulated, over-active immune response to indigenous bacteria have led to the increasing importance of immunosuppressive drugs for the therapy of IBD </plain></SENT>
<SENT sid="3" pm="."><plain>This review details the mechanisms of action, clinical efficacy, and adverse effects of these agents </plain></SENT>
</text></document>